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Herpesviruses characteristically disseminate from immune hosts. Therefore in the context of
natural infection, antibody neutralizes them poorly. Murid herpesvirus-4 (MuHV-4) provides a
tractable model with which to understand gammaherpesvirus neutralization. MuHV-4 virions
blocked for cell binding by immune sera remain infectious for IgG-Fc receptor
+ myeloid cells, so
broadly neutralizing antibodies must target the virion fusion complex – glycoprotein B (gB) or gH/
gL. While gB-specific neutralizing antibodies are rare, its domains I+II (gB-N) contain at least one
potent neutralization epitope. Here, we tested whether immunization with recombinant gB
presenting this epitope could induce neutralizing antibodies in naive mice and protect them
against MuHV-4 challenge. Immunizing with the full-length gB extracellular domain induced a
strong gB-specific antibody response and reduced MuHV-4 lytic replication but did not induce
detectable neutralization. gB-N alone, which more selectively displayed pre-fusion epitopes
including neutralization epitopes, also failed to induce neutralizing responses, and while viral lytic
replication was again reduced this depended completely on IgG Fc receptors. gB and gB-N also
boosted neutralizing responses in only a minority of carrier mice. Therefore, it appears that
neutralizing epitopes on gB are intrinsically difficult for the immune response to target.
INTRODUCTION
Herpesviruses are widespread pathogens that use immune
evasion to establish persistent infectivity in immunocom-
petent hosts (Yewdell & Hill, 2002). Most can be
neutralized in vitro. However, herpesvirus carriers not only
remain infectious, but can be superinfected (Gorman et al.,
2006) and show little tendency to select viral antigenic
variants. Therefore in the context of natural infection, virus
neutralization works poorly. Understanding why is
important, as this could potentially reveal new means of
infection control.
Studies of gammaherpesvirus neutralization have concen-
trated on Epstein–Barr virus (EBV). Antibodies to gp350
can stop EBV infecting B cells (Thorley-Lawson & Poodry,
1982). However, the gp350-specific antibodies of EBV
carriers do not render them non-infectious, and vaccina-
tion with gp350 failed to reduce the incidence of EBV
infection (Sokal et al., 2007). This could reflect gp350-
independent host entry (Janz et al., 2000), which gp350-
specific antibodies might even enhance (Turk et al., 2006).
Neutralization studies of both EBV and the Kaposi’s
sarcoma-associated herpesvirus (KSHV) have been ham-
pered by the difficulty of infecting cells at more than a very
low level. Thus, an anti-gH/gL mAb can block EBV
infection of epithelial cells, an anti-gp42 mAb can block
EBV infection of B cells (Li et al., 1995), and KSHV can be
neutralized by sera raised against the whole virus (Dialyna
et al., 2004), gH/gL (Naranatt et al., 2002), gB (Akula et al.,
2001) or K8.1 (Sakamoto et al., 2010), but much of this
neutralization has been weak (,threefold reduction in
infection) in settings where infection may be suboptimal –
for example, EBV infects epithelial cells poorly in vitro. Its
quantitative significance is therefore hard to assess.
In contrast to EBV and KSHV, murid herpesvirus-4
(MuHV-4) efficiently and productively infects a wide range
of cell types (although in vitro B-cell infection remains
problematic). It also infects mice. However, while antibody
reduces MuHV-4 lytic replication in vivo (Stevenson et al.,
1999a; Kim et al., 2002; Gangappa et al., 2002), such
protection depends on IgG Fc receptor engagement rather
than neutralization (Wright et al., 2009), perhaps because
cell association allows neutralization-resistant virus spread
(Stevenson et al., 2009). The likely key setting for MuHV-4
neutralization and its evasion – the transmission of cell-free
virions between hosts – is not yet experimentally accessible.
Nevertheless, MuHV-4 allows us to explore how gamma-
herpesvirus neutralization might be improved through
immunization.
MuHV-4 infects fibroblasts and epithelial cells by first
attaching to heparan sulfate via gp70 (Gillet et al., 2007a) or
gH/gL (Gillet et al., 2008a). These interactions can be
blocked by mAbs derived from virus carriers, and a block to Supplementary figures are available with the online version of this paper.
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stop MuHV-4 infecting fibroblasts (Gill et al., 2006).
However, the apparently neutralized virions can still infect
myeloid cells via IgG Fc receptors (Rosa et al., 2007), and the
limited capacity of immune sera to block host entry (Gillet
et al., 2007b) suggests that an equivalent rescue operates in
vivo. In contrast to this redundancy in cell binding, infection
always requires membrane fusion. Therefore, the virion
fusion machinery – gB and gH – is potentially a more
universal neutralization target, and mAbs specific for gB or
gH/gL (the predominant form of gH on extracellular
virions) can block the infection of both fibroblasts and
macrophages (Gillet et al., 2007b). However, several factors
limit the vulnerability of gB and gH to neutralization.
First, gB and gH/gL are poorly immunogenic in the context
of whole virus (Gillet et al., 2007c). Neither is conforma-
tionally stable without the other (Gillet et al., 2008b), so
native virion epitopes tend to be lost unless the gH/gL/gB
complex remains intact. In contrast, native gp150 epitopes
are preserved even in small protein fragments (Gillet et al.,
2007c). Thus gp150, which is not a neutralization target,
dominates the antibody response of MuHV-4 carrier mice.
gp150-specific antibodies both drive IgG Fc receptor-
dependent infection and tend to suppress neutralizing
responses (Gillet et al., 2007c), presumably by competition
for antigen. Boosting carrier mice with recombinant gH/gL
can overcome the immunodominance of gp150 and
improve neutralization titres; boosting with gB works less
well (Gillet et al., 2007b).
Second, a complicated entry mechanism allows key fusion
complex epitopes to remain hidden on extracellular
virions. MuHV-4 infects by endocytosis (Gill et al.,
2006). Fusion follows gH/gL dissociation in late endosomes
(Gillet et al., 2008b), when gH changes to an antigenically
very different form (gH-only). Since gH-only is inaccess-
ible pre-endocytosis, gH-specific antibodies must neutral-
ize by blocking the gH/gL to gH-only transition. gB, which
forms a complex with gH/gL (Gillet & Stevenson, 2007a),
may also not be fully revealed until after endocytosis (Gillet
et al., 2009a). The gB N terminus (gB-NT, residues 25–65)
is accessible and is a neutralization target for several
herpesviruses (Ohlin et al. 1993; Okazaki et al., 2006)
including MuHV-4 (Gillet et al., 2006), but is readily
masked by O-linked glycans, making this neutralization
strongly cell type-dependent (Gillet & Stevenson, 2007b).
Most MuHV-4 gB-specific mAbs recognize it either before
or after virion endocytosis, consistent with an extensive
fusion-associated conformation switch (Gillet et al.,
2008c). The recombinant gB extracellular domain (residues
1–724) displays mainly post-fusion epitopes. All known
pre-fusion epitopes, including all known neutralization
epitopes, lie within residues 1–423 (gB-N) (Gillet et al.,
2008c), of which residues 81–423 form gB domains I+II
(Heldwein et al., 2006). Most gB-specific neutralizing
mAbs have been IgMs and therefore difficult to reproduce
by vaccination (Gillet et al., 2006, 2008c). However, we
have recently identified a potent neutralizing IgG mAb, SC-
9E8, that recognizes gB residues 81–423 (Gillet et al.,
2009a). Delivering its epitope could therefore improve
MuHV-4 neutralization. We tested here whether recom-
binant forms of gB could elicit MuHV-4-neutralizing
antibodies and protect against MuHV-4 challenge.
RESULTS
Protection against primary MuHV-4 lytic
replication by vaccinia virus-expressed gB (VAC-
gB)
TheMuHV-4gBcan be expressedatcell surfacesindependent
of other virion components by replacing its transmembrane
and cytoplasmic domains with a glycosyl-phosphatidyl-
inositol (GPI) anchor (Lopes et al.,2 0 0 4 ) .V A C - g B - G P I
displayed both pre-fusion and post-fusion epitopes, but like
transfected gB-GPI (Gillet et al., 2008b) showed a much
greater representation of post-fusion epitopes than MuHV-4-
infected cells (Fig. 1a). Immunization intraperitoneally (i.p.)
with VAC-gB (Fig. 1b) induced a stronger gB-specific serum
antibody response than i.p. infection with MuHV-4, as
measured by flow cytometric staining of gB-GPI-transfected
CHO cells. Immunization also afforded significant protection
against intranasally (i.n.) MuHV-4 challenge (Fig. 1c).
However, sera from the immunized mice showed no
MuHV-4 neutralization (Fig. 1d). Similar results were
obtained whether sera were used fresh or after heating
(56 uC, 30 min) to inactivate complement, and whether or
not reconstituted mouse complement (Sigma Chemical Co.)
was added to the antibody-coated virions.
Expression of gB-N from vaccinia virus
We reasoned that gB-N (domains I+II) might more
effectively present pre-fusion epitopes than the full-length
extracellular domain, as it cannot switch to a post-fusion
form. The neutralization epitope recognized by mAb SC-
9E8 was presented at least as well by VAC-gB-N as by VAC-
gB, as was the distinct neutralization epitope recognized by
IgM mAb BN-6E1 (Fig. 2a). Both pooled (Fig. 2b) and
individual sera (Fig. 2c) from mice immunized with VAC-
gB or VAC-gB-N showed gB/gB-N cross-reactivity, but
substantially stronger recognition of the cognate form.
Protection against primary MuHV-4 lytic
replication by VAC-gB-N
Priming with either VAC-gB or VAC-gB-N reduced
MuHV-4 lytic replication after i.n. challenge (Fig. 3).
Viral luciferase expression (Fig. 3a, b) and plaque assays
(Fig. 3c) yielded similar results. VAC-gB protected
marginally better than VAC-gB-N, particularly in noses,
but both significantly reduced infection compared with
controls. As in previous studies (Stevenson et al., 1999b),
reducing lytic replication did not affect long-term latency
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titres were equivalent between vaccinated and unvaccinated
mice (Fig. 3d). We were more concerned whether the
protection reflected virus neutralization. Despite good gB-
specific antibody responses, sera from gB-N-primed mice
failed to neutralize MuHV-4 either as pools (Fig. 4a, b) or
as individual sera (Fig. 4c). gB-primed sera even showed a
modest enhancement of RAW-264 cell infection compared
with naive controls (Fig. 4b). Post-challenge serum
neutralization titres were also similar between vaccinated
and unvaccinated mice (Fig. 4d). Therefore, although both
gB and gB-N presented neutralizing epitopes, protection
was independent of detectable neutralization.
Protection by vaccination with gB-N depends on
IgG Fc receptors
Both neutralizing and non-neutralizing passive antibodies
reduce MuHV-4 lytic replication by IgG Fc receptor-
dependent mechanisms (Wrightetal., 2009).Theprotection
by VAC-gB-N appeared to be similar, as it was lost in IgG Fc
receptor-deficient mice (Fig. 5a). Immune sera transferred
from VAC-gB-N-immunized to naive mice also gave IgG Fc
receptor-dependent protection (Fig. 5b).
Boosting neutralizing antibody responses with
VAC-gB and VAC-gB-N
We next tested whether VAC-gB-N could boost neutral-
izing antibodies in MuHV-4 carrier mice. Previously (Gillet
et al., 2007b), it was found that VAC-gB was effective in
only a minority of mice. C57BL/6 mice infected i.n. with
MuHV-4 were 3 months later boosted i.p. with VAC-gB,
VAC-gB-N or an irrelevant VAC control. The mice were
bled before boosting, 10 days after (acute response) and
30 days after (longer-term response) (Fig. 6). VAC-gB-N
boosted gB-N-specific antibodies significantly better than
VAC-gB without improving the recognition of CHO-gB
cells, again emphasizing that gB-N and gB are antigenically
quite different (Fig. 6a). The magnitude of gB- and gB-N-
Fig. 1. Expression of gB epitopes by vaccinia virus-expressed gB and gB-N. (a) BHK-21 cells were left uninfected (UI) or
infected (1 p.f.u. per cell, 14 h) with either MuHV-4 or a vaccinia virus expressing a GPI-linked gB extracellular domain (VAC-
gB). Cell surface gB expression was analysed by flow cytometric staining of pre-fusion gB with mAb BN-1A7, and post-fusion
gB with MG-1A12. (b) C57BL/6 mice were infected i.p. with either MuHV-4 or VAC-gB. Sera collected 2 weeks later were
used to stain CHO cells either untransfected or transfected with gp70 or GPI-linked gB. Each point shows the median
fluorescence intensity for a 1/500 serum dilution from one mouse. The bars show mean values. CHO-gB staining was
significantly greater after VAC-gB infection than after MuHV-4 infection (P,0.01 by Student’s two-tailed t-test). In this and
subsequent experiments, consistent results were obtained with least two further serum dilutions. (c) Mice were immunized i.p.
with either VAC-gB or a control, and 1 month later infected i.n. with MuHV-4. Infectious MuHV-4 in lungs was plaque assayed
at 5 days post-challenge. Each point shows the titre of one mouse. The bars show geometric means. (d) Sera from mice
infected with either VAC-gB or MuHV-4 were used to neutralize eGFP
+ MuHV-4 for BHK-21 cell and NMuMG cell infections.
Infection was assayed by flow cytometry for eGFP expression 18 h after exposure to virus/antibody. Each point shows
mean±SD of triplicate infections. The dashed lines show infection with virus alone.
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individual mice (Fig. 6b). The gB-N-specific antibody
responses of non-boosted carriers (Fig. 6c) were also highly
variable, and showed no correlation with responses to full-
length gB or the MuHV-4 gp70 (Fig. 6d). Thus, even
homozygous sibling mice varied considerably in antibody
response.
Pooled C57BL/6 mouse sera (Fig. 7a) neutralized MuHV-4
for BHK-21 cell infection better after boosting with either
VAC-gB or VAC-gB-N compared with the control. Boosting
improved the neutralization of RAW-264 cell infection only
at the 10 day time point. The effects were not large, and
individual neutralization titres (Fig. 7b, c) overlapped
between groups, consistent with the varied boosting efficacy
observed by flow cytometry (Fig. 6). Thus, VAC-gB and
VAC-gB-N were both capable of boosting neutralizing
antibodies,butworkedwellinfewmice,presumably because
few mice made primary gB-specific neutralizing responses.
VAC-gB and VAC-gB-N similarlyincreasedsignificantlygB-
N- and gB-specific antibody responses in BALB/c carrier
mice (Supplementary Fig. S1, available in JGV Online) with
only a small improvement in neutralization (Supplementary
Fig. S2, available in JGV Online). As the boosting of
neutralization was similar between VAC-gB and VAC-gB-N,
the limiting factor appeared to be the composition of the
primary antibody response to MuHV-4 rather than the level
of subsequent gB-N delivery.
DISCUSSION
We sought to understand why MuHV-4-infected mice
make poor neutralizing antibody responses to gB.
Specifically, we tested whether recombinant forms of gB
containing known neutralization epitopes could stimulate
Fig. 2. Primary antibody responses to gB vaccines in C57BL/6 and BALB/c mice. (a) BHK-21 cells were left uninfected (UI) or
infected (1 p.f.u. per cell, 14 h) with vaccinia virus expressing either the full-length gB extracellular domain (VAC-gB), just its N-
terminal domains (VAC-gB-N), or a control insert (VAC-cont). gB expression was analysed by flow cytometry. mAbs BN-6E1
and SC-9E8 recognize neutralizing epitopes on pre-fusion gB. MG-1A12 recognizes a post-fusion epitope that is not
contained within gB-N. (b) Sera from mice infected i.p. 1 month previously with VAC-gB, VAC-gB-N or a control virus were
pooled from six mice per group and assayed for reactivity to gB, gB-N and gp70 (as a negative control) by flow cytometry of
transfected CHO cells. Bars show mean±SD values. For both C57BL/6 and BALB/c mice, VAC-gB-N primed CHO-gB-N-
specific responses significantly better than did VAC-gB, and VAC-gB primed CHO-gB-N-specific responses significantly
better than did VAC-gB-N (P,0.0001 by Student’s two-tailed t-test). (c) Individual sera from the C57BL/6 mice in (b) were
assayed for reactivity to gB and gB-N. Each point shows staining of the relevant CHO cells by serum from one mouse. The bars
show mean values. VAC-gB-primed mice showed significantly stronger staining of both CHO-gB (P,0.0001) and CHO-gB-N
(P,0.01), as did VAC-gB-N-primed mice (P,0.0001 by Student’s two-tailed t-test). Each group also showed significantly
stronger staining of the cognate form of gB (P,0.0001).
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Immunization with either the full-length gB extracellular
domain or its N-terminal half reduced subsequent MuHV-
4 lytic replication. However, neither construct elicited
detectable primary neutralizing responses, even though
both were recognized by a potent neutralizing mAb. Some
boosting of neutralizing antibodies in carrier mice was
possible, but the effect was not large, there was consid-
erable variation between individual mice, and gB-N was no
more effective than gB. We conclude that gB-directed
MuHV-4 neutralization is fundamentally limited by the
difficulty of targeting the few vulnerable epitopes it
presents.
How does an essential component of the MuHV-4 entry
complex avoid being a good neutralization target? It seems
likely that post-endocytic conformation changes allow key
gB epitopes to remain hidden on extracellular virions.
Thus, while gB-N binds to cells (Gillet & Stevenson,
2007b), this must occur downstream in entry as blocking
heparan sulfate binding by gp70 and gH/gL largely
abrogates virion binding (Gillet et al., 2009b). The
increased susceptibility of gL
2 virions to gB-directed
neutralization (Gillet et al., 2009a) implies that gH/gL
helps to hide gB; the regulation of virion binding by gp150
(de Lima et al., 2004) suggests that it could also be
involved. While the neutralization epitope defined by mAb
SC-9E8 is accessible it is evidently difficult to target, much
like broadly neutralizing human immunodeficiency virus
epitopes (Burton et al., 2005). Such resistance to
neutralization may be a common feature of persistent
viruses.
Herpes simplex virus (HSV) and human cytomegalovirus
(HCMV) may be more easily neutralized in vitro by gB-
specific antibodies (Cranage et al., 1986; Highlander et al.,
Fig. 3. Protection against MuHV-4 lytic replication by vaccination with gB. (a) BALB/c mice were immunized i.p. with vaccinia
viruses expressing gB, gB-N or an irrelevant insert (VAC-cont), and 1 month later challenged i.n. (10
4 p.f.u.) with luciferase
+
MuHV-4. Viral replication in lungs and noses was monitored by luciferin injection and CCD camera scanning. A representative
image is shown of mice 5 days post-challenge. (b) Mice were immunized then infected with luciferase
+ MuHV-4 as in (a). Each
point shows the luciferase signal for one mouse. The bars show mean values. Dashed lines show the lower limits of signal
detection. Priming with either VAC-gB or VAC-gB-N significantly reduced luciferase signals in lungs at all time points (P,0.03
by Student’s two-tailed t-test). Luciferase signals in noses were also significantly reduced in VAC-gB-primed mice at days 2
(P,0.01) and 5 (P,0.04), and in VAC-gB-N-primed mice at day 2 (P,0.01). (c) BALB/c or C57BL/6 mice were immunized
i.p. with vaccinia virus recombinants then challenged i.n. with MuHV-4 as in (b), but with luciferase
” MuHV-4. Lungs and noses
were titrated for infectious virus at 6 days post-infection by plaque assay. Each point shows the titre of one mouse. The bars
show geometric means. Both BALB/c (P,0.04) and C57BL/6 mice (P,0.01) lung titres were significantly reduced by priming
with either VAC-gB or VAC-gB-N. C57BL/6 mice nose titres were also reduced, although this was only statistically significant
for VAC-gB (P,0.01). (d) Latent virus loads in spleens were measured by infectious centre assay at 2 months post-challenge
of vaccinated C57BL/6 mice. The bars show mean±SD titres of five mice per group.
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membrane rather than in late endosomes: if gB conforma-
tion switches are reversible as for vesicular stomatitis virus
glycoprotein G (Roche et al., 2007) and some switching
precedes actual fusion, then mAbs specific for the post-
fusion HSV or HCMV gB could lock it non-productively in
that form. Such a mechanism would be consistent with
HSV and HCMV neutralization epitopes mapping to
prominent features of post-fusion gB (Heldwein et al.,
2006). In contrast, endocytic entry hides the MuHV-4 gB
conformation changes from antibody. HCMV may be
protected partly by competition between neutralizing and
non-neutralizing antibodies (Speckner et al., 1999), but
viral transmission would also segregate plasma membrane
fusion from the antibody in immune donors, thereby
protecting gB epitopes revealed after cell binding.
Reducing viral lytic replication may reduce transmission
events associated with primary infection, but optimally
protecting naive subjects against infection by virus carriers
is likely to require mucosal vaccination, either boosting IgA
responses in carriers or generating primary IgA responses
in naive subjects. First it is necessary to induce good
neutralization. Attention so far has focussed on IgG, since
IgG responses are more readily elicited by vaccination.
Alpha- and betaherpesvirus gB vaccine studies (Willey et al.,
1988; Nazerian et al., 1992; Pass et al., 2009) have generally
not distinguished neutralization from IgG Fc receptor-
dependent effector functions. This first description of gB
immunization against a gammaherpesvirus gave protection
consistent with the alpha- and betaherpesvirus studies, but
showed that neutralization was not involved. Therefore, it
seems unlikely that vaccination with gB alone will reduce
infection prevalence.
METHODS
Mice. C57BL/6, BALB/c, Sv129 (Harlan UK Ltd) and C57BL/
66Sv129 FcRc
2/2FccRII
2/2 mice (Taconic Europe) were housed at
the Cambridge University Department of Pathology and infected
when 6–8 weeks old under the Home Office Project Licence 80/1992.
All experiments conformed to local and national ethical regulations.
MuHV-4 (10
4 p.f.u.) was given i.n. under general anaesthesia.
Vaccinia viruses (10
6 p.f.u.) were given i.p. For luciferase imaging,
mice were injected i.p. with luciferin (2 mg per mouse), anaesthetized
with isoflurane and scanned with an IVIS Lumina (Caliper Life
Sciences). Quantitative comparisons were made by using Living
Image software. Sera were collected from tail veins, or by cardiac
puncture under terminal anaesthesia.
Cells. BHK-21 fibroblasts (ATCC CCL-10), TK
2143 cells (ATCC
CRL-8303), NMuMG epithelial cells (ATCC CRL-1636), NIH-3T3-
CRE cells (Stevenson et al., 2002), RAW-264 monocytes (ATCC TIB-
71), CHO-K1 cells (ATCC CCL-61) and CHO-K1 derivatives
expressing either gp70, the main product of ORF4 (Gillet et al.,
2007a), a fusion protein of the gH and gL extracellular domains with
a GPI anchor (Gillet et al., 2007c), or a GPI-linked gB extracellular
domain (CHO-gB) (Lopes et al., 2004), were grown in Dulbecco’s
modified Eagle’s medium (DMEM; Invitrogen Corporation) sup-
plemented with 10% FCS (PAA Laboratories), 2 mM glutamine,
100 U penicillin ml
21 and 100 mg streptomycin ml
21. To make
Fig. 4. gB-primed sera fail to neutralize MuHV-4. (a) BALB/c mice
were primed with vaccinia virus expressing gB, gB-N or a control
insert. After 1 month, sera pooled from six mice per group were
tested for their capacity to reduce BHK-21 or RAW-264 cell
infections by eGFP
+ MuHV-4, as assayed by flow cytometry 16 h
after exposure to virus. Neutralization by sera pooled from MuHV-
4-infected mice (Imm ser) is also shown. Dashed lines show the
level of infection by virus alone. (b) In a similar protocol to (a), VAC-
gB-primed and VAC-gB-N-primed sera, each pooled from six
C57BL/6 mice, showed no significant MuHV-4 neutralization. (c)
Sera from the mice in (b) were tested individually for neutralization
of BHK-21 cell infection. Again none was observed. The dashed
line shows neutralization by pooled, MuHV-4-immune sera. (d)
Sera pooled from unprimed or VAC-primed mice (n57) were
collected either before or 16 days after MuHV-4 challenge and
used to neutralize MuHV-4 virions for BHK-21 cell infection. Each
line shows mean±SEM results. No significant difference was
observed between VAC-gB-N-primed and control mice.
MuHV-4 neutralization
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cleavage site (aa 1–423) was cloned upstream of a GPI anchor
attachment site as for full-length gB (Lopes et al., 2004). CHO-K1
cells transfected with the gB-N expression plasmid were selected with
hygromycin (250 mgm l
21).
Viruses. All MuHV-4 derivatives were generated from a BAC-cloned
genome (Adler et al., 2000). Luciferase expression from an ectopic
MuHV-4 lytic promoter has been described previously (Milho et al.,
2009). The MuHV-4 BAC contains an HCMV IE1 promoter-driven
eGFP expression cassette. However, this is poorly transcribed in
some cell types (Rosa et al., 2007). Therefore to assay in vitro
infection, we inserted into the MuHV-4 genome a separate,
intergenic eGFP expression cassette with an EF1a promoter. We
first mutated the internal BglII site of the EF1a promoter in pBRAD
from AGATCT to AGGTCT by overlap PCR, then PCR-amplified
the modified promoter, adding BglII and EcoRI sites to its respective
59 and 39 ends, and cloned upstream of a poly(A) site in pSP73 (May
et al., 2005). The eGFP coding sequence was PCR-amplified from
pEGFP-N3 (Clontech), adding 59 EcoRI and 39 XhoI sites, and
cloned into EcoRI/SalI sites between the EF1a promoter and poly(A)
site. The resulting eGFP expression cassette was then subcloned as a
blunted BglII–XhoI fragment into the MfeI site of a 3.4 kb BglII
genomic clone, between the 39 ends of ORFs 57 and 58 (May et al.,
2005). Inserts here have no obvious effect on MuHV-4 replication
(Bennett et al., 2005). The eGFP expression cassette and its genomic
flanks were then subcloned into the pST76K-SR shuttle vector and
recombined into the MuHV-4 BAC by standard methods (Adler
et al., 2000). Recombinant clones were identified and checked for
genome integrity by restriction enzyme mapping. Infectious virus
was recovered by transfecting BAC DNA into BHK-21 cells. The
BAC cassette was then removed by passage through NIH-3T3-CRE
cells. Virus stocks were grown in BHK-21 cells. Virions were
harvested from infected cell supernatants by ultracentrifugation, and
cell debris removed by low speed centrifugation (de Lima et al.,
2004).
Vaccinia viruses expressing a GPI-linked gB extracellular domain or
gH/gL fusion protein have been described previously (Gillet et al.,
2007b). To make VAC-gB-N, the coding sequence for gB aa 81–423
was amplified by PCR, digested with XbaI at a site internal to gB and
cloned as a blunt XbaI fragment into the SnaBI/XbaI sites of gB in
pBRAD-gB. The predicted gB signal sequence is aa 1–24, and SnaBI
cuts after residue 22, so the coding sequence for residues 23–25 was
included in the 59 PCR primer, thereby reconstituting the native
signal sequence without residues 26–80. The modified gB-N coding
sequence plus C-terminal GPI attachment site was PCR-amplified
from pBRAD-gB-N using 59 NheI-restricted and 39 HindIII-restricted
primers and cloned into the NheI/HindIII sites of the vaccinia
recombination plasmid pMJ601 (Davison & Moss, 1990). pMJ-601-
gB-N-GPI was then transfected into vaccinia virus-infected TK
2143
cells. Thymidine kinase-deficient recombinants were selected by
passage in 25 mg5 9-bromo-29-deoxyuridine (Sigma Chemical Co.)
ml
21, identified by b-galactosidase expression using X-Gal, and
plaque purified. Virus stocks were grown and titrated using TK
2143
cells. As a TK
2 control, we used vaccinia virus expressing the mouse
invariant chain coding sequence with ovalbumin residues 323–339
substituted for the CLIP peptide (Smith et al., 2006).
Virus titres. Virus stocks and ex vivo samples were titrated for
infectivity by plaque assay on BHK-21 cells (de Lima et al., 2004).
Lungs and noses were removed from mice post-mortem, freeze–
thawed, then homogenized in DMEM. Nose samples included the
turbinates and nasal septum, which contain all the nasal luciferase
signal of mice infected with luciferase
+ MuHV-4 (Milho et al., 2009).
Serial dilutions of each sample were incubated (2 h, 37 uC) with
BHK-21 cell monolayers, then overlaid with DMEM plus 0.3%
carboxymethylcellulose. After 4 days the monolayers were fixed in
4% formaldehyde, stained with 0.1% toluidine blue and plaques were
counted with a plate microscope.
Neutralization assays. EF1a-eGFP MuHV-4 was incubated with
serum dilutions (2 h, 37 uC), then added to BHK-21 fibroblasts or
Fig. 5. Protection of naive mice and induction of MuHV-4 neutralization by vaccination with a gHL fusion protein. (a)
129SvC57BL/6 FcRc
”/”FccRII
”/” mice (FcR
”/”) or 129Sv controls were primed i.p. with vaccinia virus recombinants (10
5
p.f.u.) and 1 month later challenged i.n. with MuHV-4 (10
4 p.f.u.). Infectious virus titres in lungs and noses were measured by
plaque assay 6 days later. Each point shows the result for one mouse. The bars show geometric means. VAC-gB significantly
reduced virus replication in lungs (P,0.00001) and noses (P,0.04) of 129SV but not FcR
”/” mice. (b) Sera were pooled from
mice (n510) 3 months after i.p. infection with VAC-gB-N or VAC-cont, then given i.p. to 129Sv or FcR
”/” mice (500 ml per
mouse) at the same time as i.n. MuHV-4 (5000 p.f.u.). Lungs were titrated for infectious virus by plaque assay 5 days later. Each
point shows the result for one mouse, and the bars show geometric means. gB-N-immune sera significantly reduced virus titres
in 129Sv mice (P,0.0001 by Student’s two-tailed t-test) but not in FcR
”/” mice (P50.86).
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(100 mgm l
21) to prevent lytic spread. After 16 h, the cells were
harvested and assayed for eGFP expression by flow cytometry. In
preliminary experiments, virus titres by EF1a-driven eGFP expression
in BHK-21 cells equalled or exceeded plaque assay titres, and in
RAW-264 cells equalled or exceeded BAC cassette-associated eGFP
Fig. 6. Boosting gB-specific antibody responses by post-exposure vaccination of MuHV-4 carrier mice. (a) C57BL/6 mice
were infected i.n. with MuHV-4 and 3 months later boosted i.p. with vaccinia virus expressing either the full-length gB
extracellular domain (VAC-gB), just its N-terminal half (VAC-gB-N) or a control insert (VAC-cont). Sera were taken before
vaccinia infection (pre-boost), 10 and 30 days later, and tested for gB reactivity by flow cytometric staining of CHO cells
expressing gB or gB-N. CHO cells either untransfected or transfected with the MuHV-4 gp70 provided staining controls. Bars
show mean±SD fluorescence intensities for sera pooled from six mice each. VAC-gB-N and VAC-gB both significantly
increased CHO-gB-N staining at days 10 and 30 compared with VAC-cont (P,0.0001 by Student’s two-tailed t-test). The
increase with VAC-gB-N was significantly greater than with VAC-gB (P,0.0001). VAC-gB but not VAC-gB-N significantly
increased CHO-gB staining at days 10 and 30 compared with VAC-cont (P,0.0001). (b) Sera from the individual day 30
boosted mice in (a) were assayed for CHO-gB and CHO-gB-N reactivity. Although boosting increased staining, this did not
reach statistical significance (P.0.05) because of wide individual variation. Each point shows an individual mouse and the bars
show geometric means. (c) C57BL/6 MuHV-4 carrier mice (3 months post-infection) were analysed by flow cytometry for
serum binding to CHO-gB-N cells. Each point shows the result for one mouse. (d) A separate set of MuHV-4-infected C57BL/
6 mice were compared for serum reactivity to CHO-gB, CHO-gB-N and CHO-gp70 cells. Each point shows the result for one
mouse. There was no obvious correlation for individual mice between the responses to each target.
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2007).
Flow cytometry. Cells exposed to eGFP
+ viruses were washed twice
in PBS and analysed directly for green channel fluorescence. For
specific staining, cells were incubated (1 h, 4 uC) with MuHV-4 gB-
specific mAbs or with immune sera, followed by fluorescein-
conjugated rabbit anti-mouse IgG pAb (Dako Cytomation). mAbs
BN-1A7 (IgG2a), BN-6E1 (IgM) and SC-9E8 (IgG2a) all recognize
epitopes in gB-N and are specific for pre-fusion gB, whereas MG-
1A12 is specific for post-fusion gB (Gillet et al., 2008c). All cells were
washed twice in PBS after each antibody incubation and analysed on a
FACS Scan that runs the CellQuest software (BD Biosciences).
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